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Objectives: Thai patients have a lower average body weight than patients from western Europe or the
USA. Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per
kilogram dose is higher in Thailand than in the USA. We asked the question whether this higher per
kilogram dose was associated with more nephrotoxicity.
Methods: Thai patients from the Staccato trial were treated with tenofovir/lamivudine combined with rito-
navir-boosted saquinavir. Creatinine values were measured before the start of tenofovir and then every
12 weeks. Renal function was assessed using the Cockcroft–Gault formula and the MDRD formula. To
compare CLCR before and after tenofovir, the t-paired or Wilcoxon signed rank tests were used. One-way
analysis of variance and Spearman’s correlation coefficient were used to study CLCR longitudinally.
Results: CLCR remained stable after a median of 21 weeks on tenofovir (difference of 11.06 mL/min; 95%
CI 22.7–4.8, P5 0.58), even among patients with underlying diseases. The mean CLCR remained stable
across time (P5 0.17).
Conclusions: We did not find renal dysfunction on tenofovir among Thai patients included in the
Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai
population.
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Introduction
Tenofovir disoproxil fumarate (Vireadw; Gilead Sciences), a
nucleotide reverse transcriptase inhibitor, has demonstrated an
excellent safety profile in several controlled clinical trials1 evaluat-
ing its use for the treatment of HIV infection in previously
untreated patients. However, rare cases of nephrotoxicity have been
reported, especially in patients with a past history of renal compli-
cations or other risk factors for the development of renal disease.2
Small reductions in estimated CLCR without clinical sequelae have
been reported in some studies,3–5 but not in others.6,7 The safety
and efficacy of tenofovir disoproxil fumarate have not been
evaluated in Asian patients. A previous study showed that
saquinavir concentration was significantly higher in Thai patients
compared with UK patients, perhaps due to their lower body
weight (BW) and genetic factors.8 Here we evaluated the impact
of standard tenofovir disoproxil fumarate therapy on renal function
among Thai patients treated within the Staccato trial.9
Methods
Staccato is a randomized trial of intermittent versus continuous
antiretroviral treatment (HAART) in Thailand, Switzerland and
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Australia.9 Patients with CD4 .350 cells/mm3 and viral load (VL)
,50 copies/mL were randomized 1:2 to either continuous HAART
or scheduled treatment interruptions (STIs) (with treatment stops as
long as CD4 counts exceeded 350 cells/mm3). During Staccato,
Thai patients received ritonavir-boosted saquinavir; in addition, sta-
vudine/didanosine was administered early during the trial and then
switched to tenofovir/lamivudine in 2003. CLCR was used as a
proxy of glomerular filtration ratio and was calculated using the
Cockcroft–Gault formula and the Levey modification of diet in
renal disease formula (MDRD).8 Creatinine values (in mg/dL), BW
(in kg) and age were available before tenofovir and then measured
every 12 weeks after. In the ‘before–after group’, we compared
CLCR before and after tenofovir using t-paired tests (a ¼ 5%) or the
Wilcoxon signed rank test, when appropriate. Some patients only
had creatinine values after tenofovir (‘after-only group’) and were
thus compared with those in the before period using Student’s t-test
for independent samples (a ¼ 5%). Finally, in order to study CLCR
distribution longitudinally, we restricted our analyses to patients
from the continuous treatment arm with several creatinine values
(77.1% had at least three creatinine values after tenofovir initiation)
after 12–84 weeks on tenofovir (n ¼ 109) and used Spearman’s cor-
relation coefficient. We compared the mean CLCR between different
time periods (12–36, 36–60, 60–84 and 84–108 weeks) using
one-way analysis of variance and tested the effect of gender on
CLCR over time using two-way analysis of variance.
The Staccato protocol has been accepted by the local Ethics
Committees from the different participating centres, and written
informed consent was obtained from each participant. The
Staccato study is registered at ClinicalTrials.gov with the identifier
NCT00113126.
Results
One hundred and forty-three patients were included in the
before–after group and 121 patients in the after-only group. The
mean BW at baseline in Thai patients was significantly lower
than that in Swiss and Australian patients (57.1+10.4 versus
70.2+ 12.1 kg, P, 1023) (in women: mean weight 52.4+
7.7 kg and in men: 63.5+ 10.3 kg). Patient characteristics are
presented in Table 1.
In the before–after group, 11.2% of patients were
antiretroviral-naive at tenofovir initiation, whereas the others
were receiving stavudine/didanosine/ritonavir-boosted saquina-
vir. The mean creatinine at baseline was 0.92+ 0.36 mg/dL; it
was 0.87+ 0.23 mg/dL after a median of 21.4 weeks on tenofo-
vir [interquartile range (IQR) 15–36.3] (P ¼ 0.04). After teno-
fovir, the mean CLCR was 89.5 mL/min (D þ1.06 mL/min, 95%
confidence interval –2.71 to þ4.83, t-paired test P ¼ 0.58).
Among patients with underlying disease (n ¼ 15 with chronic
hepatitis B/C, high blood pressure or diabetes), the mean CLCR
remained stable (92.0+ 24.9 mL/min before versus 87.5+
18.9 mL/min after tenofovir, Wilcoxon signed ranks test P ¼
0.30). Four patients with baseline CLCR ,50 mL/min did not
worsen their renal function and even tended to improve it, after
a median of 23.4 weeks on tenofovir (IQR 14.7–51.7) (median
of 34.1 mL/min, IQR 23.5–40.9, before and 60.6 mL/min, IQR
31.1–79.2, after tenofovir, P ¼ 0.15).
Demographical and infection-related characteristics were
similar in both subgroups, which allow us to compare them
(Table 1). In the after-only group, tenofovir was used for a
median of 23.4 weeks (IQR 16–36). The mean creatinine was







n ¼ 121 P value
Female gender (%) 87 (60.8) 66 (54.5) 0.30
Mean age in years at
tenofovir initiation
(SD)
35.2 (+7.2) 35.8 (+6.9) 0.58
Route of infection (%) 0.001
heterosexual
intercourse
129 (90.2) 92 (76.0)
homo- or bisexual
intercourse
5 (3.5) 22 (18.2)
iv drug injection or
blood products
1 (0.7) 2 (1.7)
unknown 8 (5.6) 5 (4.1)
Mean BW before
tenofovir in kg (SD)
57.6 (+9.8) — —
Mean BW after
tenofovir in kg (SD)
57.7 (+10.1) 57.2 (+11.3) 0.73
CDC staging at baseline
(%)
0.49
A 78 (54.5) 73 (60.3)
B 49 (34.3) 37 (30.6)
C 11 (7.7) 6 (4.9)
Treatment-naive status
(%)
99 (69.2) 69 (57.0) 0.03
Mean time on tenofovir
in weeks (SD)
27.6 (+17.5) 27.1 (+15.1) 0.77
Mean CD4 count before
treatment (SD)
263.5 (+95) 235.0 (+109) 0.015
Patients with underlying
disease (%)
chronic hepatitis B 6 (4.2) 9 (7.4) 0.26
chronic hepatitis C 4 (2.8) 3 (2.5) 0.67
both chronic
hepatitis B and C
1 (0.7) 0 0.99
diabetes mellitus 1 (0.7) 2 (1.7) 0.40
high blood pressure 4 (2.8) 1 (0.8) 0.23
diabetes mellitus and
high blood pressure




BW, body weight; STI, scheduled treatment interruption.
aTwo non-radomized.
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0.91+ 0.17 mg/dL, not statistically different from creatinine
values before tenofovir in the before–after group (P ¼ 0.79).
The mean CLCR was also not statistically different at 83.8+
21.5 mL/min (P ¼ 0.13).
Using the MDRD formula in the before–after group, we
found a mean CLCR of 91.2+ 28.8 mL/min before tenofovir and
92.8+ 21.6 mL/min after tenofovir, which were not significantly
different (t-paired test P ¼ 0.46). In patients with underlying
conditions (n ¼ 15), the mean MDRD did not change between
both periods (92.3+ 24.9 mL/min before tenofovir and 88.2+
16.3 mL/min after tenofovir P ¼ 0.40). In the after-only group,
the mean CLCR using the MDRD formula was 87.7+ 17.2 mL/
min and was also not significantly different from the CLCR
before tenofovir in the before–after group (P ¼ 0.23).
In a subset of 109 continuous arm patients with creatinine
values on tenofovir at different time points (from 12 to 108
weeks), there was no correlation between CLCR and time spent
on tenofovir (Spearman’s r ¼ 0.064, P ¼ 0.18). The mean CLCR
remained stable across time (P ¼ 0.17 in ANOVA). We found
an interaction between gender and time spent on tenofovir, with
a significantly lower CLCR after 36 weeks on tenofovir in
women (CLCR 94.5+ 25.5 mL/min in men and 80.3+ 19.3 mL/
min in women), which tended to disappear after 60 weeks on
tenofovir (92.3+ 25.1 and 84.5+ 18.7 mL/min in the 60–84
week period and 83.6+ 16.2 and 77.1+ 21.2 mL/min in the
84–108 week period, in men and women, respectively). No
patient discontinued Staccato because of renal adverse events.
Discussion
We did not find renal dysfunction on tenofovir among Thai
patients included in the Staccato trial. CLCR remained stable
when time spent on tenofovir increased. The transient dip in
CLCR, observed only at 36 weeks, and only in women, may be a
statistical artefact due to multiple measurements, without clinical
significance, as CLCR at tenofovir initiation was significantly
higher among women. Nonetheless, this transient dip could also
be real in light of some other observational data, suggesting an
initial drop in CLCR on tenofovir, which does not progress with
time.5,10,11 We postulated that due to a lower BW on average,
Thai patients should have a higher exposure to tenofovir and
might be more likely to develop nephrotoxicity on the standard
300 mg daily dose. However, tenofovir disoproxil fumarate was
well tolerated, and significant renal toxicity was not observed.
Our study had some limitations, including its retrospective
nature, the lack of a control group and incomplete data on creati-
nine values at tenofovir initiation. We did not consider the rela-
tive short follow-up time of patients as a limitation. Most of the
published works had shown early changes in renal function on
tenofovir.10,11 In addition, in the primary analysis, estimates of
CLR were made using the Cockcroft–Gault formula. The
MDRD formula is considered by some to be more accurate, as
the Cockcroft–Gault formula may overestimate renal function
by as much as 16%,8 but others considered that both formulas
lacked precision.12 Moreover, MDRD has not been validated in
HIV-infected patients with normal renal function, but it was
developed as an estimate of glomerular filtration ratio in patients
with impaired renal function. The additional analyses using the
MDRD formula showed consistent results using both estimations
of glomerular filtration ratio.10 Finally, our results might differ
from those of other observational studies due to the specificity
of our study population, which was younger, with a higher CD4
count, mostly treatment-naive, with a normal renal function at
baseline and the absence of underlying diseases.9
In conclusion, Thai patients from our study treated with a
tenofovir-containing regimen were safely treated at the 300 mg
once daily standard dosage, despite their lower weight.
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